Bijoy Hans Allots ₹50.65 Cr Shares for Healthcare Acquisitions

Introduction

Bijoy Hans Limited has finalized a significant corporate action, with its Board of Directors approving the allotment of 4,05,21,836 equity shares. The preferential allotment, valued at ₹50.65 crore, is a strategic move to fund the acquisition of three companies in the healthcare sector. This transaction marks a pivotal moment for the company, substantially increasing its capital base and solidifying its transition into a healthcare-focused entity. The move follows an in-principle approval from the BSE received in February 2026, setting the stage for the company's expansion.

Details of the Share Allotment

The board approved the share issuance on a preferential basis at a price of ₹12.50 per share. The total consideration aggregates to approximately ₹50.65 crore. This capital infusion is not for cash but is structured as a share swap to acquire the target companies. Upon completion, the paid-up equity share capital of Bijoy Hans will increase from ₹7.50 crore to ₹48.02 crore, reflecting the scale of this strategic expansion.

Strategic Acquisitions in Healthcare

The primary objective of this share allotment is to facilitate the acquisition of three distinct entities, positioning them as wholly-owned subsidiaries of Bijoy Hans Limited. The acquired companies are:

1. Health Secure Hospitals Private Limited (HSHPL)
2. Arvaya Health and Wellness Pvt Ltd (AHWPL)
3. Tec-Pool Solutions Private Limited (TPSPL)

This move is a clear indicator of the company's strategic pivot towards the healthcare and wellness industry. By bringing these companies under its umbrella, Bijoy Hans aims to build a comprehensive presence in the sector, leveraging their respective strengths. The company had previously signaled this shift with a board approval in January 2026 to change its name to Arvaya Healthtech Limited, aligning its corporate identity with its new business focus.

Impact on Capital Structure

The transaction fundamentally alters the financial structure of Bijoy Hans. The company's paid-up capital will see a more than six-fold increase, jumping from ₹7.50 crore to ₹48.02 crore. This expansion follows a previous preferential allotment on May 26, 2025, where the company issued 45,00,000 equity shares, raising its capital base to the ₹7.50 crore level. The latest allotment demonstrates an aggressive growth strategy funded through equity dilution, aimed at creating long-term value in the high-growth healthcare market.

Promoter Reclassification and Shareholding Changes

A key development for investors to monitor is the pending request for the reclassification of certain promoter group members to the public category. This request follows a significant share sale on December 26, 2024, where three promoters sold their entire holdings.

This transaction triggered an open offer under SEBI regulations. The approval of the reclassification request by stock exchanges could materially alter the company's promoter shareholding dynamics, a factor that investors will be watching closely.

Regulatory Compliance and Next Steps

Bijoy Hans received in-principle approval for the preferential issue from the BSE on February 17, 2026. With the allotment now complete, the company is required to apply for listing and trading approval for the newly issued shares within twenty days. The allotted shares are also subject to a mandatory lock-in period as per SEBI (Issue of Capital and Disclosure Requirements) Regulations, restricting their sale for a specified duration.

What to Track Next

Moving forward, stakeholders should monitor three key areas. First is the successful listing of the new shares on the stock exchanges. Second is the final decision from regulatory bodies regarding the promoter reclassification requests. Finally, and most critically, will be the operational integration of the three newly acquired subsidiaries and their performance under the Bijoy Hans umbrella. The successful execution of this integration will determine the long-term success of this strategic pivot into the healthcare sector.